Information Processing at Sleep Onset and During Sleep in Patients With Insomnia

NCT ID: NCT00680199

Last Updated: 2015-10-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-06-30

Study Completion Date

2010-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic insomnia is thought to occur as a result of hyperarousal. While there is a wealth of data to support this position, there is a lack of research to define how hyperarousal interferes with sleep initiation, maintenance, and the perception of sleep quality and quantity. We propose to use Event-related Potential (ERP) techniques to evaluate information processing at sleep onset and during sleep. ERP measures of information processing have been well established in good sleepers; they have not been, however, applied to the problem of insomnia. The goal of the project is to examine the premise that the occurrence and severity of insomnia is fundamentally related to a neurobiologic preparedness to "attend to" and "identify" environmental stimuli. Following an extensive screening, patients with insomnia and good sleepers will participate in two experimental conditions, requiring that they spend four nights in the sleep laboratory over a two week period. ERP data will be gathered prior to, following, and during sleep.

The ultimate objectives for this line of research are to determine 1) if insomnia is associated with a failure to inhibit information processing at sleep onset and/or during sleep, 2) if the failure to inhibit information processing at sleep onset and/or during sleep is associated with the occurrence and/or severity of insomnia symptoms, 3) what brain regions are functioning differently so as to give rise to information processing abnormalities, and 4) the extent to which pharmacologic and/or Cognitive Behavioral treatment for insomnia alters information processing abnormalities and/or the associated brain activity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Insomnia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Primary Insomnia

No interventions assigned to this group

2

Good Sleepers

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

These subjects will meet RDC criteria for Psychophysiologic insomnia. In addition, the complaint of disturbed sleep will have at least one of the following minimal characteristics:

* \> 30 min. sleep-onset latency (SL) (Initial Insomnia)
* \>2 awakenings per night (\>15 min. ea.) and/or wake after sleep-onset (WASO) of \> 30 min (Middle Insomnia)

Total Sleep Time (TST) will not exceed 6 hours \[unless the Sleep Efficiency (SE) quotient is \< 80%\] and the problem frequency must be \> 4 nights/week (Severe Insomnia) with a problem duration \> 6 months (Chronic Insomnia)B .


* Report that they obtain enough sleep and that their sleep is restorative
* Have a score of less than 10 on the Epworth Sleepiness Scale (ESS)50-52
* Have a score of less than 15 on the Ford Insomnia Response to Stress Test (FIRST)53
* Have a score of less than 7 on the Insomnia Severity Index (ISI)54
* Report retrospectively and prospectively \< 15 minutes to fall asleep and "wake after sleep onset time" of \< 15 minutes and a total sleep time \> 6 hoursA

A These profiles will be evident at both intake (based on retrospective reports) and as an average from the two weeks of baseline diaries (based on prospective sampling).

Exclusion Criteria

• Unstable medical illness or acute or history of psychiatric illness (except GAD or MDD - Allowed provided that these have resolved and not recurred within 5 years) As ascertained with self report questionnaires, a clinical History, a physical exam and a clinical chemistry profile.

To assure that the insomnia is not secondary to these factors

* Symptoms suggestive of sleep disorders other than insomnia To assure that the insomnia is not secondary to these factors
* Polysomnographic data indicating sleep disorders other than insomnia To assure that the insomnia is not secondary to these factors
* History of head injury with a sustained loss of consciousness To help assure that the EEG measures are unconfounded by brain damage
* Evidence of active illicit substance use or fitting criteria for alcohol abuse or dependence To assure that the insomnia is not secondary to these factors
* Use of CNS active medications including antidepressants and hypnotics (within 2 weeks or 5 half-lives) To help assure that the EEG measures are unconfounded by medication effects such as the "BZ artifact".
* Inadequate language comprehension To assure the quality of self report data as all the measures are in English.
* Pregnancy Excluded owing to the hormonal changes that occur with pregnancy
* Left Handedness To control for EEG differences related to handedness
* Nicotine Use To assure that the insomnia is not secondary to these factors
* Caffeine use that exceeds 2 beverages per day or occurs past 5pm in the evening.

To assure that the insomnia is not secondary to these factors
Minimum Eligible Age

25 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institutes of Health (NIH)

NIH

Sponsor Role collaborator

University of Rochester

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sara Matteson

Clinical Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sara E Matteson-Rusby, Psy.D.

Role: PRINCIPAL_INVESTIGATOR

University of Rochester

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Rochester Sleep and Neurophysiology Research Lab

Rochester, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R21MH076855

Identifier Type: NIH

Identifier Source: secondary_id

View Link

RSRB # 20615

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Chronic Sleep Restriction
NCT01493661 COMPLETED